Adenomyosis (Investigational Palliative Adjunct)
Investigational palliative adjunct for adenomyosis-related dysmenorrhea and pelvic pain; hormonal therapy (LNG-IUD, dienogest, GnRH antagonists) and (definitively) hysterectomy remain evidence-based.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for adenomyosis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and palliative-only; in a patient with heavy menstrual bleeding the additive blood loss is itself a contraindication.
- What evidence exists?
- Tier C (investigational). No controlled trial of leech therapy for adenomyosis was identified. The reports found are largely uncontrolled Russian series in endometriosis, some including women with adenomyosis. Adenomyosis is endometrial tissue within the myometrium, producing heavy menstrual bleeding, dysmenorrhea, and chronic pelvic pain. Diagnosis is clinical-imaging (transvaginal ultrasound or MRI). Evidence-based management is hormonal: levonorgestrel-releasing IUD (Mirena), dienogest, GnRH antagonists (elagolix, relugolix combination), or combined oral contraceptives for milder disease. Definitive management for women past childbearing is hysterectomy. Uterine artery embolization is an option in selected cases.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment — additive to heavy menstrual blood loss
- Bruising and tenderness over the lower abdomen for 5 to 10 days
- Local skin infection or Aeromonas infection
- Allergic reaction to leech saliva
- Worsening anemia in patients already losing blood heavily each cycle
- Cannot reach the deep myometrial pathology through skin placement
- Delay of evidence-based LNG-IUD, dienogest, GnRH antagonists, or hysterectomy
- Missed concurrent endometrial pathology if workup is incomplete
- Who should not consider this
- Pregnant patients or those attempting pregnancy
- Patients with severe heavy menstrual bleeding requiring transfusion or with current anemia from blood loss
- Patients with suspicion of endometrial cancer or atypical hyperplasia (workup first)
- Patients within 12 weeks of abdominal or pelvic surgery
- Patients on anticoagulants
- Patients who have not trialed LNG-IUD, dienogest, or GnRH antagonists
- What to ask your clinician
- Has adenomyosis been confirmed by transvaginal ultrasound or MRI?
- Has endometrial pathology been excluded if I have abnormal bleeding patterns?
- Have I trialed LNG-IUD, dienogest, GnRH antagonists, or combined OC?
- Has hysterectomy been considered, and am I past childbearing?
- Has uterine artery embolization been considered if I want to preserve the uterus?
- Given that I bleed heavily each cycle, is adding leech-related blood loss safe in my case?
- When to seek urgent care
- Bleeding through more than one pad per hour for several hours
- Dizziness, weakness, lightheadedness, or syncope from blood loss
- Sudden severe pelvic or abdominal pain
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, or pus at any bite site
What this does NOT mean
- It does not treat or shrink adenomyosis — the deep myometrial pathology is inaccessible to topical agents.
- It does not replace LNG-IUD, dienogest, GnRH antagonists, or hysterectomy, all of which have evidence support.
- It is contraindicated when adenomyosis already causes heavy menstrual blood loss, since leech bleeding compounds anemia.
- Only uncontrolled Russian-language series in endometriosis (which included adenomyosis) exist; no controlled trial in adenomyosis was identified.
Safety cross-references
Clinical Profile
- Category
- Gynecologic
- ICD-10
- N80.0, N80.03
- Safety tier
- Medium
Evidence Summary
Adenomyosis is endometrial tissue within the myometrium, producing heavy menstrual bleeding, dysmenorrhea, and chronic pelvic pain. Diagnosis is clinical-imaging (transvaginal ultrasound or MRI). Evidence-based management is hormonal: levonorgestrel-releasing IUD (Mirena), dienogest, GnRH antagonists (elagolix, relugolix combination), or combined oral contraceptives for milder disease. Definitive management for women past childbearing is hysterectomy. Uterine artery embolization is an option in selected cases. No controlled trial of leech therapy for adenomyosis was identified in PubMed, Europe PMC or Russian-language sources. The only clinical reports are uncontrolled Russian series in genital endometriosis that included women with adenomyosis (Startseva 2005, 82 women; Startseva 2001, 41 women; Zhivoglyad and Nikonov 1998, 40 women), which report symptom relief that has not been confirmed in a controlled study. Placement is purely palliative; deep myometrial pathology cannot be addressed topically.
What the books describe
Below is a summary of what books on hirudotherapy say about this condition. These are the authors’ observations, not a proven effect and not a promise of results. Hirudotherapy has contraindications; the decision is made by a physician.
- Baskova and Isakhanyan do not write about adenomyosis; closest to the topic are the descriptions of endometriosis at various sites, and it is not clear from the text whether the patients included women with adenomyosis[B1].
- They retell the observation by Startseva et al. (2001) in 41 women with endometriosis at various sites: according to their report, the pain lessened, in 17 women the uterus became noticeably smaller, in 25 the size of the endometriosis foci, and in 37 blood loss decreased during subsequent periods[B1].
- Another description is by Zhivoglyad and Nikonov (1998): 40 patients with endometriosis, in 24 of whom, according to their report, ultrasound examination showed no residual symptoms of endometriosis[B1].
- Neither description mentions a comparison group[B1].
- Among the contraindications Baskova and Isakhanyan name hemophilia, hemorrhagic diatheses, anemias and concurrent use of anticoagulants[B1].
- On pregnancy, Baskova and Isakhanyan write that the question remains open; Michalsen et al. (the chapter on contraindications by Flecken and Michalsen) regard treatment involving blood loss as generally contraindicated during pregnancy[B1][B3].
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Pregnancy or attempting pregnancy
- Severe heavy menstrual bleeding requiring transfusion
- Acute or chronic anemia from blood loss
- Suspicion of endometrial cancer
- Recent abdominal or pelvic surgery
Related Conditions
Endometriosis-Related Pelvic Pain
Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Primary Dysmenorrhea
Investigational for primary dysmenorrhea; one small randomized trial of leeches plus cupping versus an oral contraceptive pill reported lower pain scores.
Chronic Pelvic Pain Syndrome (Non-Specific)
Investigational for non-specific chronic pelvic pain; the only clinical report located is an uncontrolled 60-woman series in which leeches were one part of multimodal care.
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use proposed for non-suppurative lactational mastitis; no clinical study of leech therapy was identified.
References
- [B1]
Баскова И.П., Исаханян Г.С. Гирудотерапия. Наука и практика [Hirudotherapy: Science and Practice]
Monograph in Russian, 506 pp., ISBN 5-89527-058-1. Chapter 15: sensation at the bite, length of the session; secretion kininases and pain.
- [B3]
Michalsen A., Roth M., Dobos G. Medicinal Leech Therapy
ISBN 978-3-13-143581-1 / 978-1-58890-563-5. Chapter 9, p. 107: perceptions of the bite — a local dragging pain lasting around one to five minutes.
The information on this page is based on the hirudotherapy books listed under References and reflects the experience their authors describe. Sensations and results differ from person to person. This information is not medical advice, a diagnosis or a prescription, and it does not replace an examination by a physician. Do not stop or change any prescribed treatment without your physician. Hirudotherapy has contraindications.